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ABSTRACT 
Cerebral palsy is a major health problem caused by brain damage during pregnancy, 
delivery, or the immediate postnatal period. Perinatal stroke, intraventricular 
hemorrhage, and asphyxia are the most common causes of neonatal brain damage. 
Periventricular white matter damage (periventricular leukomalacia) is the predominant 
form in premature infants and the most common antecedent of cerebral palsy.  
Stem cell treatment has proven effective in restoring injured organs and tissues in 
animal models. The potential of stem cells for self-renewal and differentiation translates 
into substantial neuroprotection and neuroregeneration in the animal brain, with minimal 
risks of rejection and side effects. 
Stem cell treatments described to date used neural stem cells, embryonic stem cells, 
mesenchymal stem cells, umbilical cord stem cells, and induced pluripotent stem cells. 
Most of these treatments are still experimental.  
In this review, we will focus on the efficacy of stem cell therapy in animal models of 
cerebral palsy, and we will discuss potential implications for current and future clinical 
trials.  
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INTRODUCTION 
 
Neonatal brain injuries and cerebral palsy (CP) 
Brain injury in premature infants is a major health problem worldwide. The 
incidence of preterm birth has increased, and improvements in survival rates have led to 
increased numbers of disabled patients despite a concomitant decrease in long-term 
neurodevelopmental disability rates.1-4  
Perinatal stroke, intraventricular hemorrhage, and asphyxia are the most common 
causes of neonatal brain injury, with hypoxia-ischemia being the final common pathway 
of injury.  
Periventricular white matter damage (PWMD, periventricular leukomalacia) is the 
predominant form of brain injury in premature infants and the most common antecedent 
of cerebral palsy (CP). Hypoxia/ischemia with or without systemic infection/inflammation 
is the main mechanism responsible for PWMD. Neuropathology studies show focal 
necrotic lesions within the white matter surrounding the lateral ventricles and/or the 
subsequent appearance of more widespread lesions5 related to apoptotic death of late 
oligodendrocyte progenitors.6, 7 The main neuropathological feature of PWMD is marked 
hypomyelination.8 In addition to the white matter damage, the gray matter exhibits 
abnormalities including neuronal loss and impaired neuronal guidance.9 These findings 
support the view that some of the dysfunctions seen in preterm infants reflect decreased 
brain connectivity with impairments in the integration of information arriving from 
different areas of the brain.10, 11 
Children assessed several years after preterm birth often perform less well in tests 
of cognition, attention, executive function, and perception than do children born at full 
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term.12 The massive personal and economic burdens generated by long-term 
neurological morbidity, together with the high prevalence of perinatal brain damage, are 
of considerable concern, particularly as no effective treatment is available to date.13 
 
Animal models of cerebral palsy 
Because of the many developmental and functional differences between the 
neonatal brain and the adult brain, extrapolating adult data to neonates is generally 
unwise. Consequently, the efficacy of potential treatments should be tested in 
developmentally appropriate models. Several inflammation- or ischemia/hypoxia-based 
models of CP have been developed, mainly in rodents.14 
Transient bilateral carotid artery stenosis leads to generalized brain ischemia, 
which selectively destroys specific cells. However, this model is associated with highly 
variable outcomes,15 and models of focal ischemia are therefore more commonly used. 
These models involve occlusion of the middle cerebral artery (MCA), which leads to 
infarction of the striatum and overlying cortex. Permanent occlusion is accomplished via 
laser-induced photothrombosis, ligation, or cauterization.16 Ischemia-reperfusion injury 
can be replicated by inducing transient occlusion17 using an intraluminal filament fed 
through the carotid artery into the proximal MCA. Animal models of hypoxia-ischemia 
have shown clearly that brain injury is followed by reduced myelination, ventricular 
enlargement, loss of neurons, damage to axons and dendrites, and alterations in 
neurobehavioral performance,18-21 thus reproducing common features of PWMD.  
Experimentally induced inflammation has been used in a number of studies to model 
PWMD pathology and to test potential therapeutic interventions. The endotoxin 
lipopolysaccharide (LPS), a potent inducer of innate immune responses such as 
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inflammation,22-24 administered intracerebrally during the early neonatal period or 
intraperitoneally to the pregnant dam, results in (neuro)-inflammation and 
hypomyelination in the offspring.25, 26 Excitotoxicity is another key factor that contributes 
to the development of white and gray matter damage in the premature brain.9, 27, 28 Well-
characterized animal models of excitotoxic damage involve activation of the excitotoxic 
cascade via the NMDA and metabotropic glutamate receptors. Ibotenate and quinolinate 
29 induce white matter cysts, as well as cortical necrosis, reproducing the lesions 
observed in infants with PWMD.  
 
Cell therapy  
Cell therapy holds promise in various models of brain injury or disease.30-33 Over 
the last two decades, numerous studies have evaluated the efficacy and/or feasibility of 
transplantation within the injured brain of stem cells or specialized progenitor cells of 
both neural and non-neural origin, in order to replace lost cells or to prevent damaged 
cells from dying.34, 35 However, despite the wide availability of these cells and their 
common use in animal models of injury, few studies have focused on their 
protective/regenerative effect in models of perinatal brain damage.36-42 
 
Stem cell types 
Multipotency and self-renewal are the cardinal features of stem cells. Multipotency 
is the ability to differentiate into multiple cell types belonging to the same germ layer 
(endoderm, mesoderm, or ectoderm). Self-renewal is the ability to make identical copies 
via cell division. Stem cells have considerable proliferative potential. They can be 
derived from many human tissues (Figure 1). 
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Neural stem cells (NSCs) 
NSCs are found in the adult human brain, mainly in the subventricular zone (SVZ) 
and hippocampus.43, 44 These cells give rise to the three cerebral cell types, namely, 
neurons, astrocytes, and oligodendrocytes.45 NSCs from exogenous sources can be 
isolated from many regions of the central nervous system and cultured in vitro as 
neurospheres. Neurospheres are heterogeneous cell collections that include true stem 
cells, committed progenitors, and differentiated progeny. NSCs can also be derived from 
embryonic or fetal brain tissue, and they generate oligodendrocytes, neurons, and 
astrocytes when allowed to differentiate spontaneously in serum-free media.46, 47 NSCs 
can differentiate into functional cellular subtypes48, 49 such as cortical projection 
neurons,50 interneurons,51 and hippocampal pyramidal neurons.52 
 
Embryonic stem cells (ESCs) 
ESCs are derived from blastocysts during the 16-cell stage. They are pluripotent: 
they can give rise to all cell types within the developing embryo. ESCs can provide an 
almost unlimited supply of cells for transplantation. Unfortunately, ESCs form teratomas 
after in vivo transplantation.53, 54 Purifying neural cells by removing tumorigenic 
pluripotent stem cells is feasible,55 but the resulting cell population is probably not 
different from NSCs derived from other sources. 
 
Induced pluripotent stem cells (iPSCs) 
Induced pluripotent stem cells (iPSCs) can be obtained by inducing terminally 
differentiated somatic cells via nuclear reprogramming. Reprogramming has been 
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achieved by transducing mouse56 or human57 fibroblasts with retroviral vectors 
containing cDNA encoding four genes (Oct3/4, Sox2, c-Myc, and Klf4). Recently, similar 
results were obtained by transducing fibroblasts with Oct4, Sox 2, NANOG, and LIN28,58 
a strategy having the major advantage of not using the proto-oncogene c-Myc. An 
advantage of iPSCs is the ability to generate cellular products for autologous grafts. 
Thus, the administration of iPSC-derived progenitors is not followed by a graft-versus-
host response.59 A recent study established that functional neurons, of which a small 
proportion also expressed markers of GABAergic neurons, could be obtained in mice 
from adult somatic cells without the intermediate iPSC step.60 Interestingly, the same 
procedure has been developed in humans, permitting for the first time the generation of 
hematopoietic progenitors and mature cells directly from human dermal fibroblasts, 
without establishing pluripotency.61 This strategy is ethically acceptable and, 
theoretically, eliminates the risk of tumor formation. 
 
Mesenchymal stem cells (MSCs) 
Bone marrow contains a non-hematopoietic stem cell, the mesenchymal stem cell 
(MSC). MSCs differentiate into mesodermal tissues, including bone, cartilage and fat. It 
has even been suggested that MSCs may differentiate into functional neurons.62, 63 In 
vitro, MSCs have been shown to differentiate into neurons, astrocytes, and 
oligodendrocytes.64-67 In these studies, in vitro neural transdifferentiation by MSCs was 
assessed based on the detection of neural-related mRNAs and proteins in the treated 
cells. However several neural-related mRNAs and proteins are expressed by 
undifferentiated human MSCs.68 Moreover several studies have shown that in vitro 
neuronal differentiation protocols with chemical induction medium can produce 
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unexpected and misleading effects, with cell morphology changes caused by rapid actin 
cytoskeleton disruption, cell shrinkage, and cellular toxicity.69-72 These studies indicate a 
need for a more cautious evaluation of MSC differentiation using dissection of molecular 
signaling and commitment events, in order to reliably assess the ability of MSCs to 
differentiate into neuronal lineages.  
Apart from the bone marrow, non-embryonic tissues from which MSCs can be 
isolated include cord blood and the stroma of the umbilical cord and placenta.73 MSCs 
can be expanded in vitro. This culture procedure usually takes at least 2-3 weeks, which 
is not consistent with early autologous MSC treatment after the insult. The 
immunogenicity of MSCs is extremely low, as MSCs lack expression of MHC Class-II 
antigens, which prevents the development of a graft-versus-host response. Moreover, 
MSCs have immunosuppressive activity and are even used to treat steroid-resistant 
graft-versus-host disease.74, 75 This last feature may facilitate the transplantation of 
allogeneic MSCs, thus considerably improving treatment feasibility by allowing the 
administration of stored in vitro-expanded MSCs. Apart from their regenerative capacity, 
MSCs also exhibit anti-inflammatory properties, a feature that underlines their potential 
for the treatment of cerebral injury. 
 
Umbilical cord stem cells 
Umbilical cord blood contains many stem cell types such as MSCs76 and 
endothelial progenitor cells77, and has been demonstrated as a viable alternative to 
bone marrow transplantation.78, 79 Pluripotent stem cells were recently isolated from cord 
blood.80 
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The whole mononuclear cell fraction, containing all cord blood stem cells, is easily 
obtained from cord blood and has been transplanted in different animal models with the 
goal of assessing its possible neuroprotective effects.81-84 Human umbilical cord blood 
mononuclear cells (HUCBCs) differentiate in vitro into virtually all mature cells85-89 and 
neural cells.80, 90, 91 In a few laboratories, iPSCs were recently generated from cord 
blood.92 
The many advantages of HUCBCs include ready availability with no harm to the 
baby or mother, a limited number of ethical issues, low immunogenicity,93 and beneficial 
effects in vivo in animal diseases.81, 94, 95 
The connective tissue of the cord (Wharton’s jelly) is also a promising source for 
regenerative treatments, as it can be used to generate relatively high numbers of MSCs, 
which exhibit greater proliferative activity compared to bone marrow.73, 96 
 
Strategies for stem cell therapy  
Delivery routes and methods 
Stem cells may be delivered either systemically into the vasculature or locally into 
the brain (intraparenchymally, intraventricularly, and intrathecally)52, 97 (Figure 2). Many 
stem cells are capable of migration toward a focus of injury.39 NSCs are more frequently 
delivered directly into the brain, whereas MSCs are usually given systemically. Recently, 
we showed that intranasal delivery of stem cells was a useful and non-invasive 
method.41 The stem cells cross the cribiform plate and migrate through the brain via the 
rostral migratory route.98 
 
Cell dose 
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The appropriate dose of cells for transplantation depends on several factors, of 
which the most crucial is the host environment. 99 The goal is to obtain the greatest local 
benefits using the smallest possible number of viable transplanted cells in order to 
reduce the risk of toxicity.  
In a hostile microenvironment, for instance in an area of acute brain injury, a large 
number of cells may be needed to achieve effective neuroprotection, neuroregeneration, 
and local repair modulation. However, implantation of large numbers of cells into a small 
intraparenchymal site may affect cell viability and differentiation. Moreover, when gliotic 
changes begin, the volume of cells that can be accepted physically at an injury site is 
limited, even when slow administration rates are used.100 Strategies that are being 
evaluated in several animal models include multisite intracerebral injections; prolonged 
intraventricular, intrathecal, or intravenous infusion; and repeated cell grafting over 
time.52, 97, 101, 102 Our recent studies indicate that intracranial administration of 100,000 
MSCs into the neonatal mouse brain 10 days after the insult is sufficient to improve 
outcomes.40, 103 
 
Timing of transplantation 
Most neuroprotective agents have a relatively narrow therapeutic time window to 
be effective. The window for cell therapy remains ill-defined, and the effect of stem cells 
varies across disease models. This variability reflects the ability of stem cells to act as 
neuroprotective agents, as a source of cells for in vivo replacement (neuroregeneration), 
or as both.104 Whereas neuroprotection may be suitable for the treatment of acute brain 
injury, the treatment of chronic neurodegenerative diseases requires both 
neuroprotective and cell replacement strategies. When using animal models of CP, 
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many groups transplant the cells 4 to 48 hours following acute injury. However, benefits 
have been observed with cell delivery up to 10 days after cerebral hypoxia-ischemia.41 
Such findings may suggest mechanisms of action other than neuroprotection or in 
addition to neuroregeneration, such as enhancement of endogenous cerebral plasticity.  
In acute human brain disorders such as stroke, the efficacy of therapeutic 
interventions is directly related to the time to implementation.105, 106 In animal models of 
stroke, administration of MSCs 3-24 hours after MCA occlusion diminished cell 
apoptosis by 50% in the ischemic penumbra.107-109 From a clinical point of view, whether 
stem cells are appropriate in newborns shortly after an acute brain insult is debatable. 
In this specific clinical situation, activated microglia/macrophages play a central 
pathophysiological role,110, 111 and inflammatory cytokine production by these cells may 
partly inhibit stem cell-mediated repair processes. In addition, stem cell transplantation 
may result in a systemic inflammatory response that may enhance microglial activation 
at the lesion site and worsen the white matter damage through immature 
oligodendrocyte death and oligodendroglial cell maturation arrest.7 Also, stem cell 
infusion has been associated with pulmonary thrombosis in children112, 113 and with a 
decrease in cerebral blood flow in rats.114 In acute hypoxic-ischemic injury, cerebral 
vessel occlusion after cell transplantation may dramatically worsen the effects of the 
perinatal brain insult. 
Therapeutic effects of MSCs transplanted immediately after the insult may be 
chiefly ascribable to inhibition of neuroinflammation and apoptosis. When the cells are 
administered a few days or even a few weeks after the insult, functional improvements 
may be related to endogenous repair processes such as neurogenesis, angiogenesis, 
and synaptogenesis. For the development of future therapeutic interventions, working on 
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the therapeutic window is probably crucial. More specifically, we need to investigate the 
mechanisms of action of MSCs at a given time point after the insult. To obtain proof of 
concept in mice subjected to excitotoxic injury, we compared NSC therapy given 4 or 72 
hours postinjury. The behavioral evaluation showed severe memory function 
impairments without treatment contrasting with normal memory in mice given NSCs 4 
hours postinjury. This effect was mainly due to a neuroprotective mechanism.39 Mice 
treated 72 hours after lesion showed partial memory function recovery. These data 
suggest that an intervention can be effective even when given late, after the 
inflammatory and apoptotic storm has subsided. As discussed above, inflammation 
leads to local microglial activation, inhibiting endogenous neurogenesis and suppressing 
the growth and survival of transplanted cells.115 On the other hand, inflammation also 
activates local repair, facilitating transplanted cell homing, growth, integration, and 
survival after acute injury.116-118 
Better defining therapeutic windows in CP models, as well as the 
pathophysiological mechanisms involved, may help to achieve optimal integration of the 
newly formed cells into functional networks, thereby providing histological and 
behavioral improvements.  
 
Monitoring  
Clinical studies require noninvasive methods for monitoring the migration dynamics 
and viability of transplanted cells. Currently, there is no validated method for tracking 
transplanted stem cells in human patients, as bioluminescence and fluorescence 
techniques are not suitable for use in humans. In myelin diseases, myelin formation 
analysis may allow monitoring of in vivo NSC migration and engraftment.119-121 
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Alternatively, labeling of human NSCs (HuNSCs) grown with magnetic nanoparticles 
allows NSC detection by cerebral magnetic resonance imaging (MRI) in rodents 122, 123 
and would probably be useful also in humans. Metabolic markers have been tested and 
quantified in the human brain using proton nuclear MR spectroscopy.124 Unfortunately, 
the amount of NSC metabolic biomarker decreases dramatically with increasing stem 
cell age, leading to potential misinterpretation of data. Other techniques are being 
evaluated such as the use of viral vectors to deliver genes to stem cells encoding 
proteins detectable on MRI scans.125 However, before these techniques enter clinical 
trials, the use of genetically modified HuNSCs for in vivo tracking will have to be 
approved. 
In animal studies stem cells can easily be labeled using a fluorochrome and traced 
throughout the period of regeneration.  
 
Engraftment or stimulation of endogenous regeneration? 
Originally, the positive effects of stem cell transplantation were attributed to donor 
cell engraftment in the lesion site. MSCs express neuronal proteins and differentiate in 
vitro to respond to depolarizing stimuli.64, 65, 126 Data indicate that MSCs can differentiate 
into functional neurons.62, 63 However, in a recent qPCR study of mice on postnatal day 
9 (P9), we showed that after successful intracranial eGFP+-MSC transplantation 3 and 
10 days after hypoxia-ischemia, less than 1% of the MSCs were traced 18 days after the 
last stem cell dose. Thus, at least in models of neonatal hypoxia-ischemia, MSCs may 
function merely as regulators of endogenous regeneration rather than as a substitute for 
damaged tissue (Van Velthoven et al., manuscript submitted). In this respect, it is worth 
noting that MSCs produce myriad growth and differentiation factors such as BDNF, 
Page 55 of 82
John Wiley & Sons
Annals of Neurology
Stem cells and perinatal brain damage  Titomanlio L. et al. 
15 
 
BMP, CSF, NGF, EGF, interleukins, neurotrophin, Persepin, Spp1, TGFb, VEGF, and 
others. These factors may change the local milieu, thereby acting as inducing signals 
enabling endogenous regeneration (Van Velthoven et al. manuscript submitted and40, 
41). 
 
Toxicity 
Immune response 
The central nervous system has been viewed as an immunologically isolated site 
protected by an impermeable blood-brain barrier (BBB). However, recent studies 
suggest that activated lymphocytes may cross the BBB at sites of injury and that 
resident microglia may have antigen-presenting capacity.127 Although NSCs are 
minimally immunogenic, chronic low-grade rejection of transplanted NSCs remains 
possible. Furthermore, bone marrow-derived transplants can cause an inflammatory 
response and acute rejection,128 especially when they contain CD34+ hematopoietic 
stem cells. Systemic administration of stem cells can also modify the immune response 
by modifying cytokine production.129 Clinical investigators therefore believe that some 
form of immunosuppression is necessary to optimize donor cell engraftment and survival 
in humans, by blocking T-cell activation. This strategy has been studied in only a few 
patients with Parkinson disease130, 131 or Huntington disease 132, 133 treated with fetal cell 
transplantation. Given the potentially serious side effects of immunosuppression, this 
topic will gain in importance in future clinical trials of stem cell treatments. The 
development of noninvasive means of monitoring cell engraftment will help to assess the 
need for immunosuppression.134 
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Tumors 
ESCs and iPSCs have substantial significant teratogenic potential after 
implantation into host tissues, due to their pluripotency.53, 54 Non-ESC-derived NSCs and 
MSCs are usually considered non-tumorigenic.135-138 Unfortunately, a recent report from 
Russia described a young patient with teleangiectasia ectatica who developed several 
histologically proven neuroblastomas probably derived from HuNSC transplants.139 
Because the immunodeficiency associated with telangiectasia ectatica might have 
accounted for this complication, several methods were used to demonstrate that the 
tumor was not due to chromosomal and genetic instability in the patient. The results 
supported a nonhost origin to the tumors. The NSCs used in this patient for repeated 
intracerebral transplantation were derived from periventricular tissue isolated from 
several fetuses aborted at 8-12 weeks of gestation. Conceivably, the relatively poor 
purity of these cells may have contributed, at least in part, to tumor formation in this 
patient. This report confirms the need for a detailed safety assessment of stem cell 
treatments via well-conducted clinical trials.  
 
Stem cell therapy in animal models of cerebral palsy 
Stem cell treatments have been tested in various animal models of CP. Almost all 
types of stem cells produced beneficial effects in rodents (see Table). Brain injury in 
these models is not limited to a single cell type but instead affects heterogeneous cell 
populations. This heterogeneity is desirable, as it replicates observations in humans 
after neonatal brain injury. Research on stem cell therapy in this field has therefore 
focused on a mix of progenitor cells, whereas a single cell type has often been used in 
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other developmental disorders (e.g., oligodendrocyte progenitor cells in mouse models 
of congenital demyelination140). 
Stem cell therapy has been studied chiefly in focal lesions. Focal lesions are highly 
reproducible 41, 141 and allow a histological comparison with the non-injured hemisphere. 
Another advantage of studying focal lesions is that injury to different cerebral areas 
causes different phenotypes.142-144 The efficacy of stem cell therapy in these models 
provides useful information about the pathophysiology of brain damage in full-term and 
preterm infants. 
 
Embryonic stem cells (ESCs) 
ESCs have been tested in postnatal day-12 mice with ligation of the right carotid 
artery.38 NSCs derived from ESCs by retinoic acid-induced differentiation were injected 
into the striatum 2 or 7 days after ligation, and hemispheric brain atrophy was measured 
4 weeks after ligation. Hemispheric brain atrophy was less severe in the pups treated 2 
days postligation, but not in those treated 7 days postligation, compared to vehicle-
injected ligated controls. In 3 of the 10 surviving stem cell-injected animals, the 
transplanted cells formed tumors that contained very abnormal structures.38 Teratoma 
formation appears to correlate with the degree of cell differentiation and enrichment in 
culture.145 It is possible that ESCs were transplanted with the ESC-derived NSCs, 
accounting for the tumor formation. Indeed, in transplants of cells derived from ESCs, 
the main challenge is elimination of tumorigenic cells from the progenitor populations.145 
 
Neural stem cells (NSCs) 
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The therapeutic potential of NSCs in acute neonatal brain injuries has been 
evaluated in rodent excitotoxic and ligature models. The mouse pup model of ibotenate-
induced brain injury is a classic excitotoxic injury model for white and gray matter 
damage in human cerebral palsy.141 We recently reported that early (4-hour) and late 
(72-hour) neurosphere-derived precursor cell (NDP) implantation significantly reduced 
brain lesion size in this neonatal model.39 The implanted cells, modified in vitro prior to 
transplantation toward the oligodendrocytic lineage, were capable of migrating toward 
the lesion site even when implanted contralaterally to the lesion, a feature similar to the 
long-distance migration of NSCs seen in a hypoxic-ischemic model of brain injury.118 At 
the lesion site, the NDPs underwent transient differentiation into neurons and 
oligodendrocytes but not astrocytes, suggesting that fate specification was achieved by 
the culture conditions. In parallel with the reduction in lesion size, the injured mice 
displayed a persistent and marked improvement in temporal and spatial memory at 3 
and 6 weeks of age compared to littermates given intracerebroventricular injections of 
PBS or fibroblasts. The cells finally died in situ. Thus, even NDPs that do not survive 
can modify the functional impact of brain injury in neonates.  
HuNSCs derived from ESCs were tested in mouse pups with excitotoxic lesions 
induced by the NMDA receptor agonist quinolinic acid.146 Three days after the injury, the 
mice received intraparenchymal injections of HuNSCs, which were labeled in vitro for in 
vivo tracking. The cells migrated to the sites of injury, and subsets expressed neuronal 
and glial cell markers, partially restoring the striatal neurons in the brain-damaged mice.  
More recently, HuNSCs derived from ESCs and genetically engineered for in vivo 
molecular imaging and histological tracking were tested in a rat model of permanent left 
carotid artery ligation followed by hypoxia.147 HuNSCs were transplanted in the ischemic 
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left hemisphere in the newborn pups 24 hours after the brain injury. Transplanted 
animals had significantly better behavioral performances compared to the sham-
operated controls. Bioluminescence imaging permitted real-time tracking of the grafted 
cells, which showed good survival, dispersion, and differentiation.  
 
Mesenchymal stem cells (MSCs) 
Transplantation of MSCs derived from bone marrow has been shown to promote 
functional neurologic recovery in various models of neonatal and adult cerebral damage 
and confers neurogenesis, oligodendrogenesis and axonal remodeling and rewiring.148-
150  
The overall efficacy of stem cell treatment is greater in neonatal than in adult 
models of cerebral ischemia. This difference may be ascribable to the fact that the 
potential for endogenous neurogenesis continues throughout life but declines with age, 
so that neonates have a greater potential for regenerating lost neurons compared to 
adults.151-153 We recently showed that two administrations of bone marrow-derived 
MSCs to neonatal mice 3 and 10 days after unilateral right carotid artery occlusion on 
P9 produced a 46% improvement in sensorimotor function as observed in the cylinder 
rearing test and a 60% decrease in neuronal loss, compared to vehicle-treated animals. 
Moreover, we observed cellular proliferation and differentiation of the proliferated cells 
into cells expressing neuronal, oligodendroglial and astrocyte markers. Interestingly, the 
number of proliferating microglia decreased after MSC transplantation, possibly as a 
result of the well-known anti-inflammatory effects of MSCs.40, 103 Finally, two MSC 
administrations induced extensive remodeling of the corticospinal tract with increased 
axon density and activity when analyzed by anterograde tracing with bovine dextran 
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amine or retrograde tracing with pseudo rabies virus (103 and Van Velthoven et al., 
unpublished results). Interestingly, remodeling of the corticospinal tract correlated with 
sensorimotor improvement. These data demonstrate that MSC transplantation into 
human neonates with cerebral damage may constitute a promising and realistic 
treatment modality for regenerating the damaged neonatal brain. 
 
Human umbilical cord blood mononuclear cells (HUCBCs) 
When HUCBCs were injected into non-injured neonatal rodent brains, they showed 
relatively good engraftment with 20% of cells surviving for one month.154 About 2% of 
the cells differentiated into astrocytes and neurons, indicating good adaptation to the 
host environment. In a rat model of spastic paresis induced by hypoxia-ischemia,82 
HUCBCs injected intraperitoneally 24 hours after the insult were found exclusively in the 
damaged hemisphere and exhibited no evidence of differentiation. This cell homing was 
associated with an improvement in motor function. 82 The chemokine SDF-1, which is 
secreted by astrocytes, has been suggested as an important player for attracting 
HUCBCs expressing the SDF-1 receptor (CXCR4).116 In the same model of neonatal 
hypoxic-ischemic brain damage (Rice-Vannucci model), intraperitoneal injection of 
HUCBCs 3 hours posthypoxia reduced microglial activation in the cortex and caspase-3 
mediated cell death in the striatum.81 HUCBC transplantation resulted in improved 
functional outcomes as measured using negative geotaxis and cliff aversion reflexes. 
However, contrary to the previously cited work,82 very few cells reached the injured sites 
in the cerebral cortex and striatum. Furthermore, other authors showed no cognitive 
improvement or attenuation of structural damage after the intravenous administration of 
high HUCBC doses.84 More recently, low doses of intravenously injected HUCBCs 
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induced behavioral improvements in the Rice-Vannucci rat model. This effect was 
potentiated by the use of the BBB permeabilizer mannitol and was associated with 
upregulation of brain neurotrophic factors.83 In this work, only a few cells were found in 
the injured hippocampal dentate gyrus.  
Altogether, these results indicate that experimental parameters relevant to HUCBC 
therapy, such as cell dose, timing of the injection(s), and delivery route, still need to be 
extensively investigated.  
 
Mechanisms of action: mostly hypotheses 
 Although stem cells can differentiate into neurons, oligodendrocytes, astrocytes 
and, possibly, endothelium,35, 155 neuroregeneration by cell replacement after brain injury 
might not represent their main mechanism of action. As reported above, stem cells can 
survive after transplantation, tend to migrate toward injured areas,156 and can generate 
functional neurons50 that may form connections with host cells.157 Neuroprotective39, 158 
and immunomodulatory97, 159 effects are possible mechanisms in addition to cell 
replacement.160 The effects of stem cells may include, without being limited to, 
attenuation of central nervous system inflammation, secretion of survival-promoting 
neurotrophic factors, stimulation of the plastic response or neural activity in damaged 
host tissue, and restoration of synaptic transmitter release via the provision and/or 
promotion of local re-innervation.161-165 Promotion of central nervous system repair by 
these bystander effects is due to the extraordinary capacity of in vivo stem cells to find 
the best route to certain favorable niches, where they survive and act via interaction with 
various cell types in the micro-environment.166, 167 This interaction is mainly related to 
integrins, which are proteins that act via inside-out and outside-in signaling to control 
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many cell functions such as survival, differentiation, migration, and adhesion. The varied 
integrin expression displayed by stem cells of different tissue origins and the importance 
of integrin-mediated signaling and adhesion during development highlight the need for 
elucidating the signaling mechanisms involved.168 Specific surfaces for stem cell 
derivation, maintenance, proliferation, and differentiation were developed recently. 
These surfaces mimic the complex cellular environment existing in vivo, allowing 
tailoring of tissue culture environments to individual stem cell lines, and are suitable for 
clinical applications.168, 169 
Although stem cells can survive after transplantation, long-term survival of 
engrafted cells does not seem needed to improve outcomes. Recent work by our group 
indicates that intracranially applied MSCs decline gradually, although their regenerative 
effects persist over time. Grafted stem cells induce activation of endogenous stem cell 
compartments and a global decrease in microglial activity.170 Although all these 
mechanisms have been described, the mechanisms underlying the benefits of stem cell 
therapy may vary across animal models. It is worth noting that most studies did not 
show substantial changes in both morphology and behavior after stem cell 
transplantation.84, 156, 171 However, in our studies using bone marrow-derived MSCs in a 
mouse model of hypoxia-ischemia, MSC transplantation led to recovery of sensorimotor 
function; proliferation and differentiation into neurons, astrocytes, and oligodendrocytes; 
and rewiring of the corticospinal tract.40, 41, 103 
 
Stem cell therapy in neonates with brain injury 
Clinical trials with NSCs 
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Human NSCs are becoming very attractive cells for transplantation, because of 
their stable expansion and in vitro differentiation into neurons and oligodendrocytes. 
Fetal tissue-derived NSCs have been used in preclinical mouse studies. When 
transplanted intracerebrally in mice with a disorder resembling infantile neuronal ceroid 
lipofuscinosis (NCL, Batten’s disease), these NSCs showed robust engraftment, 
extensive migration, and production of sufficient enzyme levels to alter host 
neuropathology.172 The first FDA-approved open-label, dose-escalating phase I clinical 
trial with HuNSCs was completed in January 2009 
(http://clinicaltrials.gov/ct2/show/NCT00337636). HuNSCs were transplanted into 6 
patients in the advanced stages of Batten’s disease, directly into the brain parenchyma. 
Two dose levels were tested (500 million and 1 billion cells), and patients received 
immunosuppressive therapy for 12 months. The safety profile was favorable and long-
term survival of the transplanted cells was documented. A second phase I clinical trial in 
patients with Pelizaeus-Merzbacher disease (PMD), another central nervous system 
disorder characterized by defective myelination, has received FDA approval and is 
under way at the University of California in San Francisco. This clinical trial is expected 
to enroll 4 patients with connatal PMD, who will receive stem cell transplants and 
immunosuppression for 9 months. The expected primary completion date is December 
2012 (http://clinicaltrials.gov/ct2/show/NCT01005004). 
 
Clinical trials with HUCBCs 
HUCBCs were used in a clinical trial to treat young infants with Krabbe’s 
syndrome.173 Krabbe’s syndrome is a leukodystrophy due to a disorder in the 
metabolism of galactocerebroside, one of the main lipid components of myelin. This 
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disease usually begins during the first few postnatal months, causing severe loss of 
motor skills and often death before 2 years of age. In this trial, significant improvements 
with progressive central myelination and gains in neurodevelopmental functions were 
shown only in those infants given mononuclear HUCBCs before symptom onset. Very 
recently, a pilot study of autologous cord blood infusion was performed in 184 infants 
with acquired neurological disorders.174 This retrospective study supported the safety of 
intravenous autologous HUCBC infusion. Finally, two randomized, blinded, placebo-
controlled clinical trials designed to evaluate possible beneficial effects of autologous 
umbilical cord blood infusion in infants with established CP are ongoing at the Medical 
College of Georgia (USA, http://clinicaltrials.gov/ct2/show/NCT01072370) and at the 
Duke University (USA, http://clinicaltrials.gov/ct2/show/NCT01147653), respectively. 
Based on animal models of hypoxic-ischemic encephalopathy, HUCBCs and 
MSCs may be the most promising stem cells, as they are effective and potentially 
available for human studies. HUCBCs have advantages over MSCs that may support 
their use for neonatal insults. First, HUCBCs can be harvested very easily with no harm 
to the baby or mother. They have better proliferative capacities compared to MSCs. As 
they are less mature than stem cells from adult tissues, they are probably less 
immunogenic. This feature is associated with a lower risk of graft-versus-host disease in 
recipients of transplants from unrelated donors, even when there is some degree of HLA 
mismatch.79, 93, 175 Moreover, HUCBCs have a low rate of viral infection,175 and their use 
for newborns or children is particularly appropriate as one cord usually contains a 
sufficient number of cells for use in a low-body-weight patient. Finally, the use of cord 
blood improves the availability of stem cells for ethnic groups that are under-represented 
in bone marrow donor registries. 
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Perspectives 
The most extraordinary promises held by stem cells are flexibility, adaptive growth, 
and improved host acceptance. Immunosuppression is a critically important aspect of 
moving stem cell treatments to clinical applications in humans. In the future, the need for 
immunosuppression may be obviated by the use of generated cells that are genetically 
identical to the patient.176, 177 Human mature neurons may soon be obtained from adult 
somatic cells without the intermediate iPSC step.60,61 Furthermore, given their ability to 
migrate toward areas of injury, stem cells may prove to be appropriate vehicles for 
delivering specific molecules that may not achieve sufficient concentrations in the 
injured area when given systemically.178 Candidate drugs for such ex vivo stem cell-
assisted gene therapy may include antiinflammatory, proangiogenic, and prosurvival 
molecules.179  
Current areas of concern include the risk for tumor formation, the lack of evidence 
that iPSC-derived neurons are functional, and the paucity of data indicating that stem 
cell transplantation provides clinically meaningful benefits in humans. Importantly, 
preclinical data showing neural protection should not be misinterpreted as evidence that 
these stem cell approaches are effective in patients with established CP. For the 
moment, clinical data are not available. Further studies are needed to fully understand 
the mechanisms involved in stem cell-mediated neuroprotection/neuroregeneration in 
animal models before cell therapy can be considered for newborns with CP. 
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FIGURE LEGENDS  
 
Figure 1: Neural stem cell sources, cultured in vitro as neurospheres and giving rise to 
differentiated neurons, astrocytes, and oligodendrocytes. 
 
Figure 2: Systemic and intracerebral routes of stem cell delivery to the brain.  
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Table: Stem cell types used in neonatal brain injury models.  
 
Cell type Route; time after 
injury 
Animal 
model 
Functional 
outcome 
Cellular effect Reference 
Fetal cortex 
(ED 13) 
Intracerebral; 7 
days 
P7 rats NE Graft survival 180 
Fetal cortex 
(ED 16) 
intracerebral; 3 
days 
P7 rats Improved 
performance 
NE 181 
ESCs Intracerebral; 2 
days 
P12 mice NE Decreased neural 
death 
38 
ESCs intracerebral; 2 
days 
P7 mice Improved 
performance 
Increased number 
of neurons 
182 
NSCs intraventricular; 
24 hours 
P7 rats NE Reduced brain 
damage 
183 
NSCs intracerebral; 4 
and 72 hours 
P5 mice Improved 
performance 
Reduced lesion 
size 
39 
HuNSCs intracerebral; 3 
days 
P5 mice NE Decreased neural 
death 
146 
HuNSCs intracerebral; 24 
hours 
P7 rats Improved 
performance 
Increased 
neurogenesis 
147 
MSCs intracerebral or 
intravenous; 7 
days 
P7 rats Improved 
performance 
Reduced cell loss 148 
MSCs intravenous; 3 
days 
P7 rats Improved 
performance 
No effects 184 
MSCs intracerebral; 3 
days 
P9 mice Improved 
performance 
Increased 
neurogenesis 
40 
MSCs Intranasal; 10 
days 
P9 mice Improved 
performance 
Reduced lesion 
size 
41 
MSCs intracerebral; 3 
and 10 days 
P9 mice Improved 
performance 
Reduced lesion 
size 
103 
HUCBCs intraperitoneal; 24 
hours 
P7 rats Improved 
performance 
 No reduction in 
lesion size 
82 
HUCBCs intraperitoneal; 3 
hours 
P7 rats Improved 
performance 
Decreased neural 
death 
81 
HUCBCs intravenous; 24 
hours 
P7 rats No effect No effect 84 
HUCBCs intravenous; 7 
days 
P7 rats Improved 
performance 
Increased 
dendritic density 
83 
 
ESCs, embryonic stem cells; HuNSCs, human neural stem cells; MSCs, mesenchymal 
stem cells; HUCBCs, human umbilical cord blood mononuclear cells; NE, not evaluated; 
ED, embryonic day; P, postnatal day 
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